UBS Group’s Novavax NVAX Stock Holding History

UBS Group’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.5M	Buy	+371,512	New	+$3.33M	﹤0.01%	4537
2024 Q1	–	Sell	-170,000	Closed	-$816K	–	9809
2023 Q4	$816K	Buy	170,000 +120,000	+240%	+$735K	﹤0.01%	4671
2023 Q3	$362K	Hold	50,000	–	–	﹤0.01%	4908
2023 Q2	$372K	Buy	+50,000	New	+$393K	﹤0.01%	5068
2023 Q1	–	Sell	-17,300	Closed	-$178K	–	10128
2022 Q4	$178K	Sell	17,300 -6,700	-28%	-$118K	﹤0.01%	5554
2022 Q3	$437K	Buy	+24,000	New	+$1.04M	﹤0.01%	4458
2021 Q2	–	Sell	-100	Closed	-$18K	–	9667
2021 Q1	$18K	Buy	+100	New	+$19.9K	﹤0.01%	7468
2016 Q1	–	Sell	-65	Closed	-$11K	–	8001
2015 Q4	$11K	Hold	65	–	–	﹤0.01%	7232
2015 Q3	$9K	Sell	65 -15	-19%	-$3.36K	﹤0.01%	7341
2015 Q2	$18K	Sell	80 -15	-16%	-$2.64K	﹤0.01%	6978
2015 Q1	$16K	Sell	95 -1,255	-93%	-$204K	﹤0.01%	7216
2014 Q4	$160K	Buy	+1,350	New	+$141K	﹤0.01%	5253

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

UBS Group's NVAX Position: Q2 2026 in Review

UBS Group reduced its Novavax (NVAX) stake by 58% in Q2 2026, selling an estimated $23.4M and leaving 1,869,659 shares worth $17.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2822.

UBS Group first reported a position in NVAX in Q4 2014 and has held it in 47 quarters since. The position peaked at $39M in Q4 2024. 267 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

UBS Group held 1,869,659 shares of Novavax worth $17.6M as of Q2 2026.
UBS Group sold 2,608,042 Novavax shares in Q2 2026, an estimated $23.4M.
Novavax made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2822 holding.
UBS Group first reported a position in Novavax in Q4 2014 and has held it in 47 quarters since.
UBS Group's Novavax position peaked at $39M in Q4 2024.
267 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.